190. Patterns of Retention In HIV Care And Factors Associated With Viral Suppression In Youth And Young Adults Age 18-30 With HIV In An Urban Practice

Abstract

concerns about targeted marketing, specifically the lack of campaigns focusing on transgender, female, and minority communities. Our bootstrap method of training and testing resulted in a process that had an 80% likelihood of identifying, analyzing, and classifying HIV related PrEP tweets. Once classified, 40% of tweets were advertising and messaging, the rest were concerns about cost (31%), requests for info/ ways to pay for PrEP (20%), as well as other non-classified comments. Conclusions: There are a number of different conversations about HIV/PrEP awareness happening on Twitter. However, access and cost were consistently the most common themes being discussed. Currently, a 30-day supply of PrEP costs between $0-$1600, in the US, which may be creating a substantial barrier to further reducing HIV rates. Additionally, Improving online marketing strategies of PrEP could increase awareness and use by offering targeted information as well as identification of local resources to those interested or in need. Sources of Support: NYU CAMS Undergradaute Internship 190.

Studying patterns and predictors of HIV viral suppression using A Big Data approach: a research protocol

“…According to the US CDC’s HIV Prevention Progress Report 2019, viral suppression remains lowest among persons ≤ 34 years, Blacks/African Americans, persons who inject drugs, and heterosexuals [ 18 , 19 ]. The clinical indicators of HIV diagnosis (e.g., pre-antiretroviral therapy [ART] CD4 counts, pre-ART VL level) are important in determining subsequent virologic success or failure after initiation of ART [ 16 , 19 – 21 ]. Individuals who are more immunocompromised (e.g., low baseline CD4 counts, or opportunistic illnesses) at HIV diagnosis are more likely to develop VF [ 16 , 19 – 21 ].…”

“…The clinical indicators of HIV diagnosis (e.g., pre-antiretroviral therapy [ART] CD4 counts, pre-ART VL level) are important in determining subsequent virologic success or failure after initiation of ART [ 16 , 19 – 21 ]. Individuals who are more immunocompromised (e.g., low baseline CD4 counts, or opportunistic illnesses) at HIV diagnosis are more likely to develop VF [ 16 , 19 – 21 ]. Treatment history, including earlier ART initiation [19], no prior ART use before treatment [ 20 ], prior use of mono- or dual- antiretrovirals [ 22 ], longer duration of therapy [ 20 ], and boosted protease inhibitor (PI)-based regimen [ 20 ], also impacts success or failure of sustained viral suppression [ 16 , 21 ].…”

“…Individuals who are more immunocompromised (e.g., low baseline CD4 counts, or opportunistic illnesses) at HIV diagnosis are more likely to develop VF [ 16 , 19 – 21 ]. Treatment history, including earlier ART initiation [19], no prior ART use before treatment [ 20 ], prior use of mono- or dual- antiretrovirals [ 22 ], longer duration of therapy [ 20 ], and boosted protease inhibitor (PI)-based regimen [ 20 ], also impacts success or failure of sustained viral suppression [ 16 , 21 ]. Apart from individual-level factors, considerable interest remains in understanding how social and structural determinants of health affect the HIV treatment continuum, including viral suppression.…”